AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,593.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3009
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
American Biotechnology Co., In
7658 Standish Place, Suite 107, Rockville, MD, 20855
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MICHAEL W. BASELER
PRINCIPAL INVESTIGATOR
(301) 294-9553
Business Contact:
() -
Research Institution:
n/a
Abstract
AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.THIS PROJECT INVOLVES DETERMINING THE ABILITY OF A NEW CLASS OF SYNTHETIC BIOLOGICAL RESPONSE MODIFIERS (BRM) KNOWN AS METHYLFURYLBUTYROLACTONES (MFBL) TO AUGMENT THE PRODUCTION OF LYMPHOKINES (IL-2, B-CELL GROWTH FACTOR, AND IMMUNE INTERFERON) AND MONOKINES (IL-1, PROSTAGLANDINS, AND CYTOLYTIC FACTOR). OUR LABORATORY HAS DETERMINED THAT THE MFBLS ARE POTENT IMMUNOSTIMULATORY COMPOUNDS. MFBLS ARE CAPABLE OF INCREASING THE FOLLOWING IMMUNE FUNCTIONS: 2.PRIMARY AND SECONDARY ANTIBODY PRODUCTION 3.PHAGOCYTOSIS BY BOTH MACROPHAGES AND PMNS. IT IS KNOWN THAT THE ABOVE MENTIONED IMMUNE FUNCTIONS ARE REGULATED IN SOME WAY BY LYMPHOKINES AND/OR MONOKINES. THEREFORE, WE PLAN TO INVESTIGATE THE POSSIBILITY THAT MFBLS ENHANCE THESE IMMUNE FUNCTIONS BY STIMULATING AN INCREASED PRODUCTION OF LYMPHOKINES AND/OR MONOKINES. THIS HYPOTHESIS WILL BE TESTED BOTH IN VIVO AND IN VITRO USING ESTABLISHED MURINE LYMPHOKINE AND MONOKINE ASSAY SYSTEMS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government